Asarfi Hospital Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Aug 2026 | Healthcare Services | Market Cap: ₹454 Cr
Revenue projection for FY26 is Rs.160 crores with a PAT margin of 13% to 15%. Revenue Growth**: Projected to increase from Rs.160 crores in FY26 to Rs.200+ crores by FY27.
From Asarfi Hospital Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹221
Market Cap
₹454 Cr
P/E Ratio
25.0
How does Asarfi Hospital Ltd rank in Healthcare Services?
Compare Asarfi Hospital Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Asarfi Hospital Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹45 Cr, net profit ₹4 Cr.
Full financials →📊 Revenue & Sales Performance
- →Revenue projection for FY26 is Rs.160 crores with a PAT margin of 13% to 15%.
- →For FY27, expected revenue is around Rs.200 crores with similar or slightly improved margins.
- →Target to increase total bed capacity from current 330 beds to 500 beds by FY27.
- →Plans to expand cancer hospital beds from 65 to 150, leveraging existing infrastructure, requiring minimal CAPEX.
- →Focus on ramping up cancer operations to improve occupancy and revenue.
- →Brownfield projects and possible acquisitions (including a 70-bed promoter hospital) to support bed and revenue growth.
- →Aim to eventually become a 1,000-bed company before 2030, expanding into Eastern UP, Bihar, and Jharkhand.
- →Incremental revenue expected from improved bed utilization, modest ARPOB improvements and operational synergies from acquisitions.
📈 Profitability & Margins
- →**Revenue Growth**: Projected to increase from Rs.160 crores in FY26 to Rs.200+ crores by FY27.
- →**EBITDA Margin**: Expected to improve and stabilize in the range of 25% to 27%.
- →**PAT Margin**: Targeting an increase from current ~9% to between 13% and 15% in the coming years.
- →**Bed Capacity Expansion**: Aiming to expand total bed capacity to 500 by 2027 and to 1,000 beds before 2030, supporting revenue growth.
- →**ARPOB Improvement**: Focused on marginal improvement in ARPOB while increasing bed utilization; cancer hospital ARPOB already improved significantly.
- →**Cost Optimization**: Initiatives underway to reduce costs (doctor contracts, pharmacy purchases) to enhance profitability.
- →**Receivables Management**: Efforts to reduce debtor days, particularly from government payments, to improve cash flow and profits.
- →**EPS Expectation**: With increasing revenue and improving margins, EPS growth is anticipated inline with PAT margin improvements.
🏗️ Capital Expenditure Plans
- →Expansion of cancer hospital from 65 to 150 beds; minimal CAPEX as infrastructure is mostly in place (Page 4).
- →Brownfield projects for bed expansion, focusing on reduced CAPEX and faster turnaround (Page 15).
- →CAPEX for 200-bed expansion estimated under Rs.10 crores, funded through internal accruals, to be completed before FY2027 (Page 13).
- →Construction of additional 65 beds in existing unit mostly done; equipment installation needed (~Rs.3 crores) (Page 7).
- →Rs.4 crores invested in hostel infrastructure to support manpower and paramedical/ nursing education expansion (Page 6).
- →Establishment of bone marrow transplant unit planned for next year; permission applied and facility expected operational by next year (Pages 5 and 12).
- →MOU with Gleneagles Hospital, Chennai, for multi-organ transplant unit; currently collaborating to clarify organ donation policy, no revenue projected yet (Page 12).
- →Strategic MoU signed for multi-organ transplant services in Jharkhand (Page 4).
💰 Fundraising & Capital Structure
- →No explicit mention of new fundraising through debt or equity in the provided transcript.
- →CAPEX for expansion (e.g., 200-beds) is estimated to be under Rs.10 crores and planned to be funded through internal accruals, indicating no external funding needed for this.
- →Education vertical and hostel investments (~Rs.4 crores) are being managed without large CAPEX; no mention of external funding.
- →There is discussion about acquisitions and mergers (e.g., promoter entity hospital), but no details on raising debt or equity for these.
- →The company appears focused on internal accruals and operational cash flows for funding growth and expansion rather than seeking new debt or equity at present.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Asarfi Hospital Ltd Q2 FY26 results?
Revenue projection for FY26 is Rs.160 crores with a PAT margin of 13% to 15%. Revenue Growth**: Projected to increase from Rs.160 crores in FY26 to Rs.200+ crores by FY27.
What is Asarfi Hospital Ltd share price analysis?
Asarfi Hospital Ltd currently shows a neutral. The stock trades at a P/E of 25.0 with a market cap of ₹454 Cr. Investors should review the full earnings analysis for detailed insights.
Is Asarfi Hospital Ltd planning capital expenditure?
Expansion of cancer hospital from 65 to 150 beds; minimal CAPEX as infrastructure is mostly in place (Page 4).
Keep Asarfi Hospital Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.